Efficacy of HER2 inhibitors in metastatic breast cancer by discordance in HER2 amplification status between primary and metastatic breast cancer

被引：0
|
作者：
Van Raemdonck, E.
Berteloot, P.
Laenen, A.
Han, S.
Van Nieuwenhuysen, E.
Salihi, R.
Concin, N.
Vergote, I.
Floris, G.
Wildiers, H.
Punie, K.
Neven, P.
机构：
[1] KU Leuven Univ Leuven, Leuven, Belgium
[2] KU Leuven Univ Leuven, Lab Translat Cell & Tissue Res, Leuven, Belgium
[3] Univ Leuven, Dept Pathol, Leuven, Belgium
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-PD3-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD3-09
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Van Raemdonck, Elisa
    Floris, G.
    Berteloot, P.
    Laenen, A.
    Vergote, I.
    Wildiers, H.
    Punie, K.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 183 - 194
  • [2] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Elisa Van Raemdonck
    G. Floris
    P. Berteloot
    A. Laenen
    I. Vergote
    H. Wildiers
    K. Punie
    P. Neven
    Breast Cancer Research and Treatment, 2021, 185 : 183 - 194
  • [3] HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact
    Turner, Natalie H.
    Di Leo, Angelo
    CANCER TREATMENT REVIEWS, 2013, 39 (08) : 947 - 957
  • [4] Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue
    Park, In Hae
    Kwon, Youngmee
    Ro, Jae Y.
    Lee, Keun Seok
    Ro, Jungsil
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (01) : 125 - 128
  • [5] Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue
    In Hae Park
    Youngmee Kwon
    Jae Y. Ro
    Keun Seok Lee
    Jungsil Ro
    Breast Cancer Research and Treatment, 2010, 123 : 125 - 128
  • [6] HER2 amplification and overexpression between primary and liver metastatic breast cancer: Significance and implication
    Williams, Casey B.
    De, Pradip
    Klein, Jessica
    Williams, Kirstin Anne
    Cyr, Brigitte
    Small, Misty
    King, Michelle
    Carlson, Jennifer
    Sun, Yuliang
    Young, Brandon Michael
    Willis, Scooter
    Dey, Nandini
    Krie, Amy K.
    Leyland-Jones, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [7] Evolution of low HER2 expressions between primary and metastatic breast cancer
    Tarantino, P.
    Nicolo, E.
    Zagami, P.
    Giugliano, F.
    Trillo A, P.
    Marra, A.
    Trapani, D.
    Morganti, S.
    Mazzarella, L.
    Criscitiello, C.
    Esposito, A.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S33 - S33
  • [8] Comparison of hormonal receptor expression and HER2 status between primary and metastatic breast cancer
    Alves, A.
    Ortiz, S.
    Luis, P.
    Correia, L.
    VIRCHOWS ARCHIV, 2013, 463 (02) : 268 - 268
  • [9] HER2 overexpressing metastatic breast cancer.
    Spigel D.R.
    Burstein H.J.
    Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
  • [10] Somatic mutations of the HER2 in metastatic breast cancer
    Fang, Yi
    Jiang, Yanxia
    Wang, Xin
    Yang, Xue
    Gao, Yinqi
    Wang, Jing
    TUMOR BIOLOGY, 2014, 35 (12) : 11851 - 11854
12345